Stockscreener 앱 받기
2.135
8.46%
-0.195
전일 마감가:
$2.33
열려 있는:
$2.26
하루 거래량:
1.12M
Relative Volume:
0.79
시가총액:
$67.16M
수익:
-
순이익/손실:
$-69.00M
주가수익비율:
-0.768
EPS:
-2.78
순현금흐름:
$-55.26M
1주 성능:
+7.72%
1개월 성능:
+11.66%
6개월 성능:
+51.26%
1년 성능:
-72.83%
1일 변동 폭
$2.11
$2.30
1주일 범위
$1.88
$2.46
52주 변동 폭
$1.05
$8.74
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
명칭
Acrivon Therapeutics Inc
전화
617-207-8979
주소
480 ARSENAL WAY, SUITE 100, WATERTOWN
ACRV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
2.135 | 73.29M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
420.52 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
626.68 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.19 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
831.00 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.24 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-05 | 재개 | Piper Sandler | Overweight |
| 2025-01-31 | 개시 | KeyBanc Capital Markets | Overweight |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2024-04-29 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2024-03-01 | 개시 | JMP Securities | Mkt Outperform |
| 2023-12-15 | 재개 | Jefferies | Buy |
| 2023-10-05 | 개시 | Maxim Group | Buy |
| 2023-06-02 | 개시 | Oppenheimer | Outperform |
| 2023-05-08 | 개시 | BMO Capital Markets | Outperform |
| 2023-04-27 | 개시 | Ladenburg Thalmann | Buy |
| 2023-04-20 | 개시 | H.C. Wainwright | Buy |
| 2022-12-12 | 개시 | Cowen | Outperform |
| 2022-12-12 | 개시 | Jefferies | Buy |
| 2022-12-12 | 개시 | Piper Sandler | Overweight |
모두보기
Acrivon Therapeutics Inc 주식(ACRV)의 최신 뉴스
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 42.6% in October - MarketBeat
3 Promising Penny Stocks With Market Caps Over $20M - simplywall.st
How does Acrivon Therapeutics Inc (ACRV) change from a tortoise to a hare? - setenews.com
Will Acrivon Therapeutics Inc. stock benefit from green energy trendsInflation Watch & Target Return Focused Picks - newser.com
Is Acrivon Therapeutics Inc. stock attractive for hedge fundsRecession Risk & Precise Buy Zone Tips - newser.com
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? - ts2.tech
Is Acrivon Therapeutics Inc. stock a contrarian buyIPO Watch & Short-Term Swing Trade Alerts - newser.com
Is Acrivon Therapeutics Inc. stock supported by strong cash flows2025 Momentum Check & Weekly Sector Rotation Insights - newser.com
Will Acrivon Therapeutics Inc. stock split attract more investors2025 Trading Recap & Consistent Growth Stock Picks - newser.com
What high frequency data says about Acrivon Therapeutics Inc.Weekly Trend Recap & AI Driven Price Predictions - newser.com
Custom strategy builders for tracking Acrivon Therapeutics Inc.July 2025 Macro Moves & Long-Term Growth Stock Strategies - newser.com
Can Acrivon Therapeutics Inc. stock weather global recessionMarket Performance Report & AI Forecast for Swing Trade Picks - newser.com
Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks - Yahoo Finance
Why Acrivon Therapeutics Inc. stock is recommended by analystsJuly 2025 Closing Moves & Community Verified Trade Signals - newser.com
Will Acrivon Therapeutics Inc. rebound enough to break evenDip Buying & Free Reliable Trade Execution Plans - newser.com
Acrivon Therapeutics’ Phase 1 Study of ACR-2316: Key Updates and Market Implications - TipRanks
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks
Acrivon Therapeutics Inc (ACRV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.18%
0.56%
자본화:
|
볼륨(24시간):